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Abstract
Sphingosine kinases (SKs) are key enzymes regulating
the production of sphingosine-1-phosphate (S1P), which
determines important cell responses including cell
growth and death. Here we show that renal mesangial
cells isolated from wild-type, SK-1-/-, and SK-2-/- mice
show a differential response to apoptotic stimuli. Wild-
type mesangial cells responded to staurosporine with
increased DNA fragmentation and caspase-3 processing,
which was enhanced in SK-1-/- cells. In contrast, SK-2-/-
cells were highly resistant to staurosporine-induced
apoptosis. Furthermore, the basal phosphorylation and
activity of the anti-apoptotic protein kinase B (PKB) and
of its substrate Bad were decreased in SK-1-/- but not in
SK-2-/- cells. Upon staurosporine treatment, phosphory-
lation of PKB and Bad decreased in wild-type and
SK-1-/- cells, but remained high in SK-2-/- cells. In addi-
tion, the anti-apoptotic Bcl-XL was significantly upregu-
lated in SK-2-/- cells, which may further contribute to the
protective state of these cells. In summary, our data
show that SK-1 and SK-2 have opposite effects on the
capacity of mesangial cells to resist apoptotic stimuli.
This is due to differential modulation of the PKB/Bad
pathway and of Bcl-XL expression. Thus, subtype-selec-
tive targeting of SKs will be critical when considering
these enzymes as therapeutic targets for the treatment
of inflammation or cancer.
Keywords: apoptosis; ceramide; mesangial cells;
sphingosine-1-phosphate; sphingosine kinase knockout
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Introduction
Although sphingolipids exert their main function as struc-
tural components of cellular membranes, it has become
clear that some sphingolipid species also have critical
functions as signalling molecules and regulate a variety
of physiological and pathophysiological processes such
as cell growth and differentiation, cell migration and
adhesion, and apoptosis (Huwiler et al., 2000; Futerman
and Hannun, 2004; Huwiler and Pfeilschifter, 2006).
Sphingomyelin is the main precursor of this class of
signalling molecules. Upon exposure of cells to various
stress factors such as proinflammatory cytokines, oxi-
dative and nitrosative stress, UV- and g-irradiation, and
chemotherapeutics, sphingomyelinases are activated
and hydrolyse sphingomyelin to generate ceramide.
Ceramide is further degraded by ceramidases to sphin-
gosine, which in turn serves as a substrate for sphingo-
sine kinases (SKs) to generate sphingosine-1-phosphate
(S1P). In contrast to ceramide and sphingosine, which
both can trigger an apoptotic cell response, S1P acts to
counterbalance this response and stimulates cell prolif-
eration and protects cells from apoptosis. This has led
to the hypothesis of a cellular sphingolipid rheostat in
which ceramide and S1P counter-regulate each other’s
functions (Hait et al., 2006).
SKs are critical enzymes regulating the cellular levels
of S1P and thus may ultimately control cell fate. SKs are
ubiquitously expressed and exist as two subtypes, SK-1
and SK-2 (Alemany et al., 2007). The physiological func-
tions of these two isoforms are still not fully clear. SK-1
has been attributed a key function in cell proliferation and
migration, and upregulation of SK-1 mRNA has been
reported for several tumour tissues and cell lines (French
et al., 2003; Do¨ll et al., 2005, 2007; Alemany et al., 2007).
In line with this, recently developed inhibitors of SK-1 are
effective in reducing tumour cell growth in vitro and
tumour growth in mice (French et al., 2003, 2006). In con-
trast, SK-2 has been attributed a pro-apoptotic function
based on cellular transfection experiments (Liu et al.,
2003). SK-2 contains a BH3 domain, which was reported
to interact with Bcl-XL and inhibit its protective potential,
consequently resulting in cell apoptosis. By interrupting
the SK-2/Bcl-XL interaction by site-directed mutagenesis
of Leu219 in murine SK-2, Bcl-XL could exert its full pro-
tective effect and apoptosis was prevented (Liu et al.,
2003). Furthermore, overexpression of SK-2 in various
murine and human cell lines was shown to block DNA
synthesis (Igarashi et al., 2003; Okada et al., 2005), which
was abrogated by mutation of Arg93 and Arg94 of SK-2
(Igarashi et al., 2003).
In the present study we used renal mesangial cells iso-
lated from wild-type, SK-1-deficient or SK-2-deficient
mice and exposed them to the potent apoptotic trigger
staurosporine. We show that SK-1-deficient cells are
more prone to apoptosis. In contrast, SK-2-deficient cells
are highly protected from staurosporine-induced apop-
tosis. Furthermore, the PKB/Bad signalling cascade was
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Figure 1 Effect of staurosporine on DNA fragmentation, annex-
in V-FITC binding, and caspase-3 processing in wild-type, SK-
1-deficient and SK-2-deficient mouse mesangial cells.
Quiescent mouse mesangial cells isolated from either wild-type
(Wt), SK-1-deficient (SK1ko) or SK-2-deficient mice (SK2ko)
were stimulated for 6 h with either vehicle (0) or the indicated
concentrations of staurosporine in the presence of 1% FBS.
Then cells were scraped and subjected to a DNA fragmentation
ELISA (A), flow cytometry with detection of annexin V-FITC and
7AAD staining (B), or SDS-PAGE and Western blot analysis of
cleaved caspase-3 (C, upper panel) or b-actin (C, lower panel)
at dilutions of 1:1000 and 1:10 000, respectively, as described
in the materials and methods section. Data in (A) are expressed
as a percentage of control values and are mean"SD (ns3).
*p-0.05, ***p-0.001 significantly different compared to wild-
type control values, p-0.01 compared to wild-type 10 nM
staurosporine values, §§p-0.01 compared to wild-type 30 nM
staurosporine values. Results in (B) show the percentage apop-
totic cells (annexin V-FITC-positive and 7AAD-negative) and are
the mean for two independent experiments. Data in (C) are
representative of four independent experiments giving similar
results.
poorly activated in cells lacking SK-1, whereas cells lack-
ing SK-2 exhibited robust PKB/Bad activation and con-
stitutive upregulation of anti-apoptotic Bcl-XL.
Results
Characterisation of primary cultures of mesangial
cells isolated from SK-deficient mice
To study the cellular functions of SK-1 and SK-2, we
used primary cultures of renal mesangial cells from SK-
1-deficient, SK-2-deficient and C57BL/6 control mice.
Mesangial cells cultured from glomeruli isolated from kid-
neys of SK-1-deficient and SK-2-deficient mice showed
no mRNA or protein expression of the corresponding
knockout enzyme compared to wild-type C57BL/6 cells
(data not shown).
Differential response to apoptotic stimulation
of mesangial cells derived from SK-1 and SK-2
knockout mice
To evaluate whether SK-1 and/or SK-2 have a relevant
function in the apoptotic machinery, we investigated the
influence of SK-1 and SK-2 deficiency in mesangial cells
on DNA fragmentation induced by staurosporine treat-
ment.
Stimulation of wild-type mesangial cells with low doses
(10 and 30 nM) of staurosporine led to a dose-dependent
increase in DNA fragmentation (Figure 1A). In SK-1-defi-
cient mesangial cells, staurosporine evoked a signifi-
cantly higher amount of DNA fragmentation compared to
wild-type cells (Figure 1A). In contrast, SK-2-deficient
cells showed considerably less DNA fragmentation upon
staurosporine treatment than wild-type cells (Figure 1A).
As an additional early marker of apoptosis, phosphatidyl
serine exposure on the outer leaflet of the plasma
membrane was measured by flow cytometry with detec-
tion of annexin V-FITC and 7-aminoactinomycin (7AAD)
staining. As observed in Figure 1B, annexin V-FITC bind-
ing to apoptotic cells strongly increased in SK-1-deficient
cells, but drastically decreased in SK-2-deficient cells.
These data suggest opposite cellular functions of SK-1
and SK-2 in the regulation of mesangial cell apoptosis.
SK-1 may exert a cell protective effect, but still allows
staurosporine to induce apoptosis. Deletion of SK-1
leads to loss of this protection, which allows a higher rate
of apoptosis by an apoptotic trigger. In contrast, deple-
tion of SK-2 either removes a harmful signal or induces
a protective mechanism and strongly prevents stauro-
sporine-induced apoptosis.
To determine whether the altered DNA fragmentation
observed in SK-1 and SK-2 knockout cells is also detect-
ed in the apoptosis signalling cascade, caspase-3 pro-
cessing was investigated. Caspase-3 is considered an
executioner caspase located far downstream in the
apoptotic event, but still preceding DNA fragmentation
(Boatright and Salvesen, 2003). Western blot analyses of
the different primary cell cultures stimulated with stau-
rosporine were performed. As observed in Figure 1C,
cleaved caspase-3, which represents the active enzyme
and runs at a size of 18 kDa, increased upon stauro-
sporine treatment of wild-type cells, confirming many
previous reports that staurosporine is able to activate
caspase-3 (Yue et al., 1998). In SK-1-deficient cells, stau-
rosporine-activated caspase-3 was enhanced compared
to wild-type cells, whereas caspase-3 was activated to a
lesser extent in SK-2-deficient cells (Figure 1C). b-Actin
expression was similar in all three primary cell cultures,
confirming equal loading.
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Figure 2 Effect of staurosporine on PKB expression and phos-
phorylation in wild-type, SK-1-deficient and SK-2-deficient
mouse mesangial cells.
Quiescent mouse mesangial cells isolated from wild-type (Wt),
SK-1-deficient (SK-1ko) or SK-2-deficient mice (SK-2ko) were
stimulated for 6 h with either vehicle (Co) or staurosporine (stau,
10 nM) in the presence of 1% FBS. Then cell lysates containing
50 mg of protein were separated by SDS-PAGE, transferred to
nitrocellulose and subjected to Western blot analysis using anti-
bodies against phospho-Ser473-PKB (inset, upper panel), total
PKB (inset, middle panel), or b-actin (inset, lower panel) at dilu-
tions of 1:1000, 1:1000 and 1:10 000, respectively. Bands were
visualised by the ECL method according to the manufacturer’s
instructions, and were densitometrically evaluated. Data are pre-
sented as a percentage of the control and are mean"SD (ns4).
*p-0.05, ***p-0.001 significantly different compared to wild-
type control values, p-0.05 compared to SK2ko vehicle-stim-
ulated values, §§§p-0.001 compared to SK1ko vehicle-
stimulated values.
Figure 3 Effect of staurosporine on Bad expression and phos-
phorylation in wild-type, SK-1-deficient and SK-2-deficient
mouse mesangial cells.
Quiescent mouse mesangial cells isolated from wild-type (Wt),
SK-1-deficient (SK1ko) or SK-2-deficient mice (SK2ko) were
stimulated for 6 h with either vehicle (Co) or staurosporine (stau,
10 nM) in the presence of 1% FBS. Then cell lysates containing
50 mg of protein were separated by SDS-PAGE, transferred to
nitrocellulose and subjected to Western blot analysis using anti-
bodies against either phospho-Ser136-Bad (inset, upper panel) or
total Bad (inset, lower panel) at dilutions of 1:500 each. Bands
were visualised by the ECL method according to the manufac-
turer’s instructions, and were densitometrically evaluated. Data
are presented as a percentage of the control and are mean"SD
(ns4). ***p-0.001 significantly different compared to wild-type
control values, p-0.05, p-0.01 compared to SK-1ko vehi-
cle-stimulated values.
Expression profiles of the anti-apoptotic factors
PKB, Bad, Bcl-2 and Bcl-XL in SK-1- and
SK-2-deficient cells
To investigate whether the altered rate of apoptosis in
SK-1- and SK-2-deficient cells is due to a dysfunction of
the cell-protective PI 3-kinase/protein kinase B (PKB)/
Bad signalling pathway, we determined the phosphory-
lation state of PKB and Bad. PKB contains a phos-
phorylation site at Ser473, which is supposedly either an
autophosphorylation site or phosphorylated by another
protein kinase, tentatively named PKB Ser473 kinase or
PDK2 (Alessi et al., 1996; Persad et al., 2001; Hill et al.,
2002). Phosphorylation of this site is always coupled to
increased kinase activity (Alessi et al., 1996; Persad et
al., 2001; Hill et al., 2002). Incubation of wild-type cells
for 6 h in DMEM supplemented with 1% FBS resulted in
a considerable basal level of phospho-Ser473 PKB (Figure
2 inset, upper panel). This constitutive phosphorylation
was drastically lower in SK-1-deficient cells, whereas in
SK-2-deficient cells, phospho-Ser473 PKB was even
amplified (Figure 2 inset, upper panel). Staurosporine
stimulation decreased the amount of phospho-Ser473
PKB in wild-type cells, which is consistent with increased
apoptosis. In SK-1-deficient cells, phospho-Ser473 PKB
levels remained low after staurosporine treatment
(Figure 2 inset, upper panel). Importantly, phospho-Ser473
PKB levels in SK-2-deficient cells were only slightly lower
after staurosporine treatment and remained significantly
higher than in wild-type cells (Figure 2 inset, upper
panel). Total PKB levels were not altered in wild-type or
SK-1- or SK-2-depleted cells and did not change upon
staurosporine stimulation (Figure 2 inset, middle panel).
In addition, b-actin remained constant in the different cell
lines and did not change upon stimulation (Figure 2 inset,
lower panel).
Active PKB can phosphorylate Bad at Ser136 and thus
inactivates the pro-apoptotic Bad, leading to cell protec-
tion (Datta and Brunet, 1999). We found that phospho-
rylation of Bad at Ser136 in the presence of 1% FBS was
drastically decreased by staurosporine not only in wild-
type cells, but also in SK-1-deficient cells, whereas in
SK-2-deficient cells phosphorylation of Bad remained
high and was hardly affected by staurosporine (Figure 3).
Collectively, these data suggest that SK-1-deficient cells
have a lower protective capacity due to disturbed PKB
activation, whereas SK-2-deficient cells have a high pro-
tective capacity that, at least in part, is due to persistent
PKB activation and Bad phosphorylation upon exposure
to stress stimuli.
Since cell apoptosis may also be regulated by the
expression levels of other anti-apoptotic factors, partic-
ularly Bcl-2 (Osford et al., 2004; Kim, 2005) and Bcl-XL
(Boise et al., 1993; Kim, 2005), we next investigated
these factors. Interestingly, mouse mesangial cells lack-
ing SK-2 expressed much higher levels of Bcl-XL protein
compared to either wild-type or SK-1-deficient cells
(Figure 4A inset, upper panel). SK-1-deficient cells even
exhibited slightly lower Bcl-XL expression compared to
wild-type cells, which could contribute to the more apop-
tosis-prone state of these cells. In contrast, Bcl-2 protein
expression did not significantly change in any of the cell
lines (Figure 4A inset, lower panel). Staurosporine treat-
ment of cells caused partial downregulation of Bcl-XL
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Figure 4 Protein expression profile of the anti-apoptotic fac-
tors Bcl-XL and Bcl-2 in wild-type, SK-1-deficient, and SK-2-
deficient mouse mesangial cells and whole kidney extracts.
Protein lysates from mouse mesangial cells (A) or whole kidneys
(B) from wild-type (Wt), SK-1-deficient (SK-1ko) or SK-2-defi-
cient mice (SK-2ko) were separated by SDS-PAGE, transferred
to nitrocellulose and subjected to Western blot analysis using
specific antibodies against Bcl-XL (inset in A, upper panel; dilu-
tion 1:1000), b-actin (inset in A, middle panel; dilution 1:10 000),
and Bcl-2 (inset in A, lower panel; dilution 1:500) as indicated.
Bands were visualised by the ECL method according to the
manufacturer’s instructions and densitometrically evaluated.
Densities corresponding to Bcl-XL protein are depicted as per-
centage of control values and are mean"SD (ns4). *p-0.05,
**p-0.01, ***p-0.001 significantly different compared to corre-
sponding wild-type control values. Insets in (A) show three out
of four samples.
Figure 5 Bcl-XL and Bcl-2 mRNA expression levels in mesan-
gial cells from wild-type, SK-1-deficient and SK-2-deficient
mice.
RNA extracts of mouse mesangial cells isolated from wild-type
(Wt-mMC), SK-1-deficient (SK1ko-mMC), or SK-2-deficientmice
(SK2ko-mMC) were subjected to quantitative PCR analysis of
Bcl-XL (open columns), Bcl-2 (closed columns) and 18S RNA
expression. DDCt values were calculated using iQ5 Optical Sys-
tem Software Version 2.0 from Bio-Rad. Data are expressed as
a percentage of wild-type expression levels and are mean"SD
(ns4), ***p-0.001 significantly different compared to wild-type
control values.
Figure 6 Quantification of S1P, sphingosine and C16-ceramide
in wild-type, SK-1-deficient and SK-2-deficient mice.
Mouse mesangial cells were isolated from wild-type (Wt), SK-1-
deficient (SK1ko), or SK-2-deficient mice (SK2ko) for lipid
extraction and then subjected to LC/MS/MS as described in the
materials and methods section. Results are expressed as ng/105
cells of C16-ceramide (C16-cer), sphingosine (Sph), or S1P, and
are mean"SD (ns3). *p-0.05, ***p-0.001 significantly different
compared to wild-type control values.
protein expression in all primary cell cultures (63% in Wt
cells, 80% in SK1ko cells, and 25% in SK2ko cells),
although the effect in SK-2-deficient cells was small.
Staurosporine had no effect on Bcl-2 expression (data
not shown). These data confirm previous data in other
cell types that also showed downregulation of Bcl-XL by
staurosporine (Giuliano et al., 2004) and other pro-apop-
totic stimuli (Liu and Stein, 1997; Saltzman et al., 1998;
Weinmann et al., 1999). Furthermore, cell lysates of
whole kidneys from SK-2-deficient mice exhibited signif-
icantly enhanced protein expression of Bcl-XL (Figure
4B), but not of Bcl-2 (data not shown). In SK-1-deficient
kidney lysates, no significant changes in Bcl-XL (Figure
4B) or Bcl-2 protein levels (data not shown) were
observed. Moreover, the increased Bcl-XL expression in
SK-2-deficient cells, but not in SK-1-deficient cells, was
also reflected at the mRNA level (Figure 5). Again, Bcl-2
mRNA expression did not change in wild-type, SK-1-
deficient or SK-2-deficient mesangial cells (Figure 5).
Finally, to determine whether these changes in anti-
apoptotic factors can be attributed to the accumulation
of a certain sphingolipid species, we quantified the three
main bioactive sphingolipids, C16-ceramide, sphingosine
and S1P, in the three primary cell cultures. Surprisingly,
neither SK-1-deficient nor SK-2-deficient cells showed a
clear decrease in cellular S1P levels (Figure 6), suggest-
ing that compensatory mechanisms may be involved.
Only SK-2-deficient cells showed a drastic accumulation
of sphingosine. The levels of C16-ceramide remained
very low in all three cell cultures and even significantly
decreased in SK-2-deficient cells compared to wild-type
cells (Figure 6).
Discussion
In this study we show for the first time that SK-1 and SK-
2 in renal mesangial cells have opposite cellular functions
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in regulating cell survival and cell death. Lack of SK-1
causes increased sensitivity towards an apoptotic trigger,
whereas lack of SK-2 renders the cells more resistant
and protects them from undergoing apoptosis. This sug-
gests that SK-1 protects cells, whereas SK-2, when
active, may have pro-apoptotic potential.
It is well reported in the literature that the balance of
the two sphingolipids ceramide and S1P determines the
cell’s fate to either proliferate or undergo apoptosis
(Huwiler et al., 2000; Futerman and Hannun, 2004;
Huwiler and Pfeilschifter, 2006). Much evidence has been
presented in recent years indicating that S1P is both a
mitogenic and a survival factor, whereas ceramide has
pro-apoptotic potential (Huwiler et al., 2000; Futerman
and Hannun, 2004; Huwiler and Pfeilschifter, 2006). How-
ever, our data now suggest that this concept does not
accurately reflect reality. Although the two SKs theoretic-
ally generate the same product, i.e., S1P, they have
opposite effects on cell survival. This suggests that the
subcellular site of S1P generation, the duration and
strength of signals generated, or potential interacting
partner recruited, just to name a few possibilities, are crit-
ical for the cell response. It cannot be excluded that the
differential effects observed are due to other functions of
SKs independent of their kinase activities and S1P gen-
eration. This arises from our findings that cellular S1P
levels hardly changed in SK-deficient cell cultures,
although cell responses were strongly affected. Only in
SK-2-deficient cells did sphingosine accumulate as
expected. However, it is unlikely that this increase in
sphingosine is responsible for the cell protective capacity
in these cells, as sphingosine is normally considered a
pro-apoptotic molecule (for a review see Huwiler et al.,
2000). Previous studies by other groups also revealed
unexpected results regarding sphingolipid levels in SK-
1- and SK-2-deficient mice and tissues. In this context,
Zemann et al. (2006) reported that serum S1P levels in
SK-2-deficient mice increased, but decreased by
approximately 50% in SK-1-deficient mice. Moreover,
Michaud et al. (2006) measured S1P levels in forepaw
tissue and found only slight decreases in SK-1-deficient
mice. Recently, Mizugishi et al. (2007) generated SphK1-
/-SphK2q/- mice and investigated uterine decidualisation.
When measuring S1P levels in uteri, there was no differ-
ence between wild-type and SphK1-/-SphK2q/- mice. In
contrast, S1P levels measured in SK-1-deficient or SK-
2-deficient embryonic E11.5 tissue was drastically lower,
and completely absent in double knockout embryonic
tissue. However, this was not accompanied by an accu-
mulation of sphingosine (Mizugishi et al., 2005).
In a previous study using cultured fibroblasts and HEK
293 cells, Maceyka et al. (2005) proposed opposite reg-
ulatory effects of SK-1 and SK-2 on ceramide biosynthe-
sis. By downregulating SK-2 by siRNA, they showed a
decrease in ceramide formation, whereas downregulation
of SK-1 by siRNA resulted in increased ceramide for-
mation. Our data did not reveal increased C16-ceramide
levels in SK-1-deficient cells, but we found significantly
lower levels in SK-2-deficient cells (Figure 6). However,
the C16-ceramide levels measured were generally very
low and it is not clear whether such small changes are
responsible for the effects observed. Still, it may be
argued that C16-ceramide is only one ceramide subspe-
cies, albeit the most abundant, and higher levels are
reached when summing all ceramide subspecies and the
decrease in SK-2-deficient cells is more drastic.
So far, few data are available on the subcellular loca-
lisation of the two SK subtypes. In this context, Kleuser
et al. (2001) showed that in Swiss 3T3 fibroblasts over-
expressing green fluorescence protein-coupled SK-1, the
enzyme was equally localised in the cytoplasm and in the
nucleus and that the nuclear fraction of SK-1 was acti-
vated upon PDGF stimulation. Indeed, sequence analysis
of SK-1 revealed a nuclear export signal that directs
export of SK-1 from the nucleus to the cytoplasm and
suggests constant ‘shuttling’ of the enzyme (Inagaki et
al., 2003). Upon activation, cytoplasmic SK-1 can also
translocate to the plasma membrane, which requires
phosphorylation of the enzyme by ERK (Pitson et al.,
2005).
A nuclear localisation signal (NLS) has been identified
at the N-terminal sequence of SK-2 (Igarashi et al., 2003),
which actively directs SK-2 to the nucleus. Functionally,
it was shown that the nuclear localisation of SK-2 is cou-
pled to inhibition of DNA synthesis, since mutation of two
nucleotides (Arg93 and Arg94) of the NLS of murine SK-2
abolished the inhibitory effect on DNA synthesis. In addi-
tion, the generation of a ‘chimeric’ SK-1 containing the
NLS of SK-2 at its N-terminus was able to mimic the
inhibitory effect on DNA synthesis (Igarashi et al., 2003).
Moreover, it was shown that nuclear SK-2 can be phos-
phorylated by the protein kinase D, which is also known
as protein kinase C-m, resulting in export of SK-2 to the
cytoplasm (Ding et al., 2007). All these data suggest that
there are subcellular pools of sphingolipids and that the
knockout of either SK-1 or SK-2 may lead to subcellular
and local changes in sphingolipid levels that are not
detectable using our total cell lipid extraction method.
The mechanisms by which S1P acts as a survival fac-
tor may include various overlapping or non-overlapping
signalling cascades. In particular, activation of the PI
3-kinase/PKB pathway by S1P, as reported for various
cell types (Igarashi et al., 2001; Robert et al., 2001;
Davaille et al., 2002) including renal mesangial cells (Xin
et al., 2004), may strongly promote cell survival mecha-
nisms. Activated PKB phosphorylates Bad at Ser136 and
thus renders this pro-apoptotic factor inactive (Blume-
Jensen et al., 1998; Datta and Brunet, 1999).
Our data suggest that SK-1 positively regulates the
cell-protective PKB/Bad pathway. Consequently, SK-1-
deficient cells have drastically lower levels of phospho-
rylated and hence activated PKB and its substrate Bad.
Whether this mechanistically involves an autocrine mode
of action of S1P via secretion and subsequent activation
of cell-surface S1P receptors or an intracellular action of
S1P, or is even independent of S1P, remains unclear. So
far, most evidence in the literature supports S1P recep-
tor-mediated activation of the PI3K/PKB cascade. How-
ever, intracellular S1P can activate signal transduction
and acutely triggers intracellular Ca2qmobilisation (Meyer
zu Heringdorf et al., 2003) and stimulates cell proliferation
of fibroblasts (van Brocklyn et al., 1998).
In contrast, cells lacking SK-2 have a constitutively
active PKB/Bad pathway (Figures 2 and 3) and are more
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resistant to apoptotic stimuli (Figure 1). In addition, these
cells have highly upregulated expression of the anti-
apoptotic Bcl-2 family member Bcl-XL. How the absence
of SK-2 is mechanistically coupled to PKB/Bad activation
and Bcl-XL upregulation is unknown, but strongly points
to a nuclear suppressive effect of SK-2 on cell signalling
and gene transcription that is lost upon SK-2 depletion.
In this context, it is known that Bcl-XL expression is upre-
gulated by many anti-apoptotic stimuli (Boise et al.,
1993; Sevilla et al., 2001; Kim, 2005) and that this is par-
tially due to transcriptional activation of the gene. The
Bcl-XL promoter has been cloned (Grillot et al., 1997;
MacCarthy-Morrogh et al., 2000) and sequence analyses
revealed various binding sites for transcription factors
such as NF-kB, Ets, STAT and AP1 (Sevilla et al., 2001).
Thus, it is tempting to speculate that one of the Bcl-XL-
regulating transcription factors is also constitutively acti-
vated in SK-2-deficient cells. Clearly, further studies are
needed to address this in detail. In addition, it was report-
ed that ERK and PKB/Akt cooperatively upregulate Bcl-
XL expression (Suzuki et al., 1998). In view of this study,
the increased expression of Bcl-XL observed in SK-2-
deficient cells could also be a consequence of the
increase in PKB activation. It is well known that PKB cou-
ples to various transcription factors including the fork-
head transcription factor FOXO, the tumour suppressor
p53, and NF-kB (Brunet et al., 2001).
Limaye et al. (2005) showed that S1P generated by
SK-1 overexpression in endothelial cells exerted a cell
protective effect due to activation of PKB and specific
upregulation of Bcl-2. On the other hand, it was shown
that cellular overexpression of Bcl-2 in A-375 cells mark-
edly stimulated SphK1 expression and activity, whereas
downregulation of Bcl-2 decreased SphK1 expression
(Bektas et al., 2005). The relationship between Bcl-2 and
SK-1 seems to be cell-type-specific, because no signif-
icant changes in Bcl-2 mRNA or protein expression were
caused by either SK-1 or SK-2 depletion in renal mesan-
gial cells (Figure 4A) and, importantly, in whole kidney
(data not shown). Moreover, in human T-lymphoblastoma
cells, the cell protective effect of S1P was independent
of Bcl-2 and Bcl-XL (Goetzl et al., 1999).
In summary, our data demonstrate that SK-1 and
SK-2 have opposite effects on stress-induced apoptosis
in renal mesangial cells. The absence of SK-1 makes
cells prone to apoptosis, whereas the absence of SK-2
protects cells from undergoing apoptosis. This provides
an example of how a specific signal, i.e., the generation
of S1P, can be interpreted differentially at the level of
gene expression and functional cell response. A future
challenge will be to elucidate the structure of wiring of
the SphK/S1P signalling pathway to its physiological
partners in the cell and finally to determine the functional
consequences of these interactions.
Materials and methods
Chemicals
Secondary anti-rabbit and anti-mouse horseradish peroxidase-
coupled IgGs, Hyperfilm MP, and enhanced chemiluminescence
(ECL) reagents were from GE Health Care Systems GmbH (Frei-
burg, Germany). Antibodies against active caspase-3, phospho-
Ser136-Bad, total Bad, phospho-Ser473-PKB/Akt, Bcl-XL, and
Bcl-2 were from Cell Signaling (Frankfurt, Germany). Total PKB/
Akt-1 was from Santa Cruz Biotechnology (Heidelberg,
Germany). b-Actin (clone AC-15) antibody and staurosporine
were from Sigma Aldrich Fine Chemicals (St. Louis, MO, USA).
The DNA fragmentation ELISA was from Roche Diagnostics
(Mannheim, Germany) and the annexin V-FITC/7-aminoactino-
mycin (7AAD) apoptosis assay kit was from Beckman Coulter
(Krefeld, Germany). All cell culture nutrients were from Life Tech-
nologies (Karlsruhe, Germany).
Cell culture
SK-1-deficient and SK-2-deficient mice were generated by
Genoway (Lyon, France) and backcrossed to C57BL/6. Mouse
renal mesangial cells were isolated from C57BL/6 control mice
and SK-1-deficient and SK-2-deficient mice as previously
described (Klawitter et al., 2007). Outgrown mesangial cells were
subcultured and further used up to passage 8. Cells were
characterised by positive staining for smooth muscle a-actin
and negative staining for cytokeratin (to exclude epithelial cell
contamination). The growth medium was RPMI containing 15%
fetal bovine serum (FBS), 10 mM HEPES, pH 7.4, 100 U/ml pen-
icillin, 100 mg/ml streptomycin, 6 mg/ml bovine insulin, 5 mg/ml
transferrin, 5 ng/ml sodium selenite and 4.5 mg/ml b-mercapto-
ethanol.
Cell stimulation and Western blot analysis
Confluent mesangial cells in 60-mm-diameter dishes were ren-
dered quiescent by incubation for 1 day in serum-free Dulbec-
co’s modified Eagle medium (DMEM) containing 0.1 mg/ml fatty
acid-free bovine serum albumin (BSA) and 1% FBS. Cells were
then stimulated as indicated. To stop the stimulation, the medi-
um was withdrawn and the cells were washed once with ice-
cold phosphate-buffered saline (PBS) solution. Cells were
scraped into ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA, 2 mM
EGTA, 40 mM b-glycerophosphate, 50 mM sodium fluoride,
10 mg/ml leupeptin, 10 mg/ml pepstatin A, 1 mM phenylmethyl-
sulfonyl fluoride) and homogenised by 10 passes through a 26G
needle fitted to a 1-ml syringe. Lysates were then centrifuged
for 10 min at 13 000 g and the supernatant was analysed for
protein content. Equal amounts of protein (50 mg) were sepa-
rated by SDS-PAGE and transferred to nitrocellulose mem-
branes and subjected to Western blot analysis as previously
described (Huwiler et al., 1995).
Quantitative real-time PCR
Samples of 3 mg of total RNA isolated using TRIZOL reagent
were subjected to RT-PCR (first-strand synthesis kit, MBI, Vil-
nius, Lithuania) using a random hexamer primer for amplification.
The following primer sequences were used: mouse SK-1, for-
ward 59-CCT GGA GGA GGC AGA GAT AAC C-39, reverse 59-
CCG TTC CAT TAG CCC ATT CAC C-39; mouse SK-2, forward
59-GCA CGG CGA GTT TGG TTC C-39, reverse 59-TGT ATG TGT
AGG GCT TGT GTT GTG-39; mouse Bcl-XL, forward 59-TCT GAA
TGA CCA CCT AGA GCC TTG-39, reverse 59-AGA ACC ACA
CCA GCC ACA GTC-39; mouse Bcl-2, forward 59-TCC TTC CAG
CCT GAG AGC AAC-39, reverse 59-CAC GAC GGT AGC GAC
GAG AG-39; and mouse 18S RNA, forward 59-CGA TTC CGT
GGG TGG TGG TG-39, reverse 59-CAT GCC AGA GTC TCG TTC
GTT ATC-39. The reporter dye was SYBR green. The PCR buffer
was from Bio-Rad (Munich, Germany). After cDNA synthesis,
0.2 ml of the product (0.02 ml for 18S RNA) was used for further
analysis. Runs were performed on an iQ5 Cycler (Bio-Rad) at
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958C for 15 min, followed by 40 cycles of 958C for 15 s and
588C for 1 min. iQ5 Optical System Software Version 2.0 from
Bio-Rad was used to analyse real-time and endpoint fluores-
cence. Fold induction values were obtained according to the
DDCT method.
DNA fragmentation ELISA
Cells in 6-well plates were stimulated as indicated and removed
for DNA fragmentation ELISA according to the manufacturer’s
instructions.
Flow cytometric analysis of cell death
Exposure of phosphatidyl serine (PS) on the extracellular surface
of the plasma membrane, which is an early marker of apoptotic
cells, was determined using an annexin-V-FITC/7-aminoactino-
mycin (7AAD) apoptosis assay kit. Quiescent mesangial cells in
6-well plates were stimulated as indicated. To stop the stimu-
lation, the medium was withdrawn and the cells were washed
once with ice-cold PBS. Cells were then harvested by trypsin-
isation and cell pellets were resuspended at a concentration of
6=106 cells/ml binding buffer. PS-expressing cells were stained
with annexin-V FITC, and the DNA of apoptotic and necrotic
cells was stained with 7AAD according to the manufacturer’s
instructions. Cytofluorometric analyses were performed using
FACSCalibur (Becton Dickinson, San Jose, CA, USA). A total of
10 000 cells was collected for each sample. Viable cells were
defined as annexin V-FITC-negative and 7AAD-negative cells.
Apoptotic cells were defined as annexin V-FITC-positive and
7AAD-negative, and necrotic cells as annexin V-FITC-positive
and 7AAD-positive cells. Analyses of the multivariate data were
performed using CELLQuest, which is part of the FACSCalibur
operating system.
Sphingolipid quantification by LC/MS/MS
Confluent cells in 6-well plates were removed for lipid extraction
according to Bligh and Dyer (1959) and parallel cell counting. As
internal standards, C17-ceramide (5 ng/ml), C17-S1P (20 ng/ml)
and C17-sphingosine (20 ng/ml) (Avanti Polar Lipids Inc., Ala-
baster, AL, USA) were added to the lipid extraction samples.
Dried lipids were redissolved in dimethylsulfoxide including 2%
HCl and subjected to LC/MS/MS according to Schmidt et al.
(2006).
Statistical analysis
Statistical analysis was performed by one-way analysis of vari-
ance (ANOVA). For multiple comparisons with the same control
group, the limit of significance was divided by the number of
comparisons according to Bonferroni.
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